Market Data 
Markets
Replies to post #244705 on Biotech Values
05/16/23 2:22 AM
Amgen Inc.’s $27.8 billion deal to buy Horizon Therapeutics Plc, the largest in the biotechnology company’s history, will be challenged by federal regulators who argue the tie-up would hamper innovation and slow the pace of drug development, according to a person familiar with the matter.
The Federal Trade Commission is expected to file a lawsuit to block the purchase on Tuesday, the person said, asking not to be identified discussing private information. A suit would mark the first time in more than a decade that the FTC has sought to block a pharma merger outright [i.e. rather than mandating divestitures—Dew].
AI
